CDK4/6 inhibitors in Breast Cancer Therapy examines the pivotal role of CDK4/6 inhibition in treating hormone receptor-positive (HR+)/HER2-negative advanced breast cancer. The book highlights FDA-approved applications of these inhibitors alongside endocrine therapy and explores ongoing research into their potential as neoadjuvant treatments. It provides insights into the drug discovery and development of CDK4/6 inhibitors, covering their molecular mechanisms, pharmacology, and clinical applications. Chapters address their use in mono and adjuvant therapies, as well as challenges in targeting, while also discussing market potential and post-marketing safety issues.This book is a valuable resource for researchers and academics, enhancing understanding of CDK4/6 inhibitors' chemistry and therapeutic implications. By presenting detailed information on clinical trials and market formulations, it equips the audience with essential knowledge to navigate the complexities of targeted breast cancer therapies and contributes to advancing research in this critical area. - Provides comprehensive insights into drug discovery and development processes of CDK4/6 inhibitors, detailing the molecular mechanisms and pharmacological aspects relevant to targeted breast cancer therapy- Explores the current clinical applications of CDK4/6 inhibitors, including their use in mono and adjuvant therapies- Discusses market potential and the post-marketing safety issues associated with CDK4/6 inhibitors
